Paion - Near-term filings in the US and Japan on track

Donnerstag, 07.02.2019 14:21 von Edison Investment Research

Paion is approaching several important milestones, with partners on track to file for approval of remimazolam in the US, Japan and Russia in the next few months. Its Phase III study of remimazolam in general anaesthesia (GA) in Europe is progressing well and is on track to complete recruitment in 2019, while partner R-Pharm recently completed a successful Phase III in GA in Russia. The filings will be an important step towards establishing Paion as a leader in acute and critical care. We have made minor revisions to the timing of R&D expenditure in line with revised guidance and rolled forward our DCF model, which lifts our valuation to €291m or €4.56/share.